These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17329190)

  • 21. The relationship between the insulin-like growth factor-1 system and the oestrogen metabolising enzymes in breast cancer tissue and its adjacent non-cancerous tissue.
    Chong YM; Colston K; Jiang WG; Sharma AK; Mokbel K
    Breast Cancer Res Treat; 2006 Oct; 99(3):275-88. PubMed ID: 16752221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
    Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of ErbB2 gene status, mRNA and protein expression in a panel of >100 human tumor xenografts of different origin.
    Kuesters S; Maurer M; Burger AM; Metz T; Fiebig HH
    Onkologie; 2006 Jun; 29(6):249-56. PubMed ID: 16770086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Presence of erbB2 mRNA in the plasma of breast cancer patients is associated with circulating tumor cells and negative estrogen and progesterone receptor status.
    Xu Y; Yao L; Li H; Ouyang T; Li J; Wang T; Fan Z; Lin B; Lu Y; Larsson O; Xie Y
    Breast Cancer Res Treat; 2006 May; 97(1):49-55. PubMed ID: 16319978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strong association between c-myb and oestrogen-receptor expression in human breast cancer.
    Guérin M; Sheng ZM; Andrieu N; Riou G
    Oncogene; 1990 Jan; 5(1):131-5. PubMed ID: 2181374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
    Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M
    Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real time RT-PCR approach for the evaluation of ERBB2 overexpression in breast cancer archival samples: a comparative study with FISH, SISH, and immunohistochemistry.
    Capizzi E; Gruppioni E; Grigioni AD; Gabusi E; Grassigli A; Grigioni WF; Fiorentino M
    Diagn Mol Pathol; 2008 Dec; 17(4):220-6. PubMed ID: 18382352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Hormone-dependence and C-ERBB2: relationship between estrogen receptor expression, estrogen-regulated proteins, and C-ERBB2 in breast carcinoma].
    Costarelli L; Piro FR; Fortunato L; Vitelli CE; Farina M; Taffuri M; Amini M
    Suppl Tumori; 2005; 4(3):S171. PubMed ID: 16437968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.
    Brase JC; Schmidt M; Fischbach T; Sültmann H; Bojar H; Koelbl H; Hellwig B; Rahnenführer J; Hengstler JG; Gehrmann MC
    Clin Cancer Res; 2010 Apr; 16(8):2391-401. PubMed ID: 20371687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
    Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
    Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative measures of oestrogen receptor and ERBB2 expression.
    Hayes DF
    Lancet Oncol; 2007 Mar; 8(3):184-5. PubMed ID: 17329185
    [No Abstract]   [Full Text] [Related]  

  • 33. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen.
    Girault I; Lerebours F; Amarir S; Tozlu S; Tubiana-Hulin M; Lidereau R; Bièche I
    Clin Cancer Res; 2003 Apr; 9(4):1259-66. PubMed ID: 12684393
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative multi-methodological measurement of ERBB2 status in breast cancer.
    Ginestier C; Charafe-Jauffret E; Penault-Llorca F; Geneix J; Adélaïde J; Chaffanet M; Mozziconacci MJ; Hassoun J; Viens P; Birnbaum D; Jacquemier J
    J Pathol; 2004 Mar; 202(3):286-98. PubMed ID: 14991893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.
    Bilous M; Morey A; Armes J; Cummings M; Francis G
    Pathology; 2006 Apr; 38(2):120-4. PubMed ID: 16581651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
    Salido M; Tusquets I; Corominas JM; Suarez M; Espinet B; Corzo C; Bellet M; Fabregat X; Serrano S; Solé F
    Breast Cancer Res; 2005; 7(2):R267-73. PubMed ID: 15743507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
    Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY
    Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array.
    Andre F; Job B; Dessen P; Tordai A; Michiels S; Liedtke C; Richon C; Yan K; Wang B; Vassal G; Delaloge S; Hortobagyi GN; Symmans WF; Lazar V; Pusztai L
    Clin Cancer Res; 2009 Jan; 15(2):441-51. PubMed ID: 19147748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor signalling pathway.
    Dorssers LC; van Agthoven T; Brinkman A; Veldscholte J; Smid M; Dechering KJ
    Breast Cancer Res; 2005; 7(1):R82-92. PubMed ID: 15642172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
    Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
    Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.